Landmark Bio Partners with Mass General Brigham to Accelerate Cell and Gene Therapy Development
Key Insights
Landmark Bio (search) has established a new collaboration with Mass General Brigham (search) to provide development and manufacturing services for cell and gene therapies originating from the health system.
The partnership enables Landmark Bio (search) to support early-stage translational research and development for advanced therapies through collaboration with Mass General Brigham (search)'s Gene and Cell Therapy Institute (search).
The agreement creates a framework for accelerating therapeutic innovation from bench to bedside, with both organizations sharing a mission to bring breakthrough therapies to patients faster.
Landmark Bio (search), LLC announced the initiation of a strategic collaboration with Mass General Brigham (search) on October 15, 2025, to provide comprehensive development and manufacturing services for cell and gene therapies originating from the health system. The partnership establishes a framework for advancing Mass General Brigham-originated cell and gene therapies through collaboration with the health system's Gene and Cell Therapy Institute (search) (GCTI).
Collaboration Framework
The agreement enables Landmark Bio (search) to support early-stage translational research and development for advanced therapies across the Mass General Brigham (search) system. The collaboration creates a direct pathway for projects aimed at accelerating therapeutic innovation from bench to bedside, addressing the critical gap between laboratory discoveries and clinical applications.
"This collaboration underscores our shared mission to bring breakthrough therapies to patients faster," said Ran Zheng, chief executive officer of Landmark Bio (search). "Working with the exceptional teams at the Mass General Brigham (search) Gene and Cell Therapy Institute (search), we are excited to provide the infrastructure and expertise that can help translate cutting-edge science into real-world impact."
Strategic Alignment
Roger J. Hajjar, M.D., head of the Gene and Cell Therapy Institute (search) at Mass General Brigham (search), emphasized the alignment between the organizations' missions. "The GCTI exists to help realize the promise of cell and gene therapies developed by investigators across Mass General Brigham," Hajjar stated. "This collaboration with Landmark Bio (search) reflects our commitment to translational science and working together with collaborators to move transformative therapies forward."
Company Profile and Capabilities
Landmark Bio (search), headquartered in Watertown, Massachusetts, was founded by leading academic institutions, research hospitals, and industry partners to accelerate the development, manufacturing, and commercialization of advanced therapies. The company focuses on the transformative potential of genetic medicine and offers deep drug development expertise alongside integrated end-to-end solutions to support its partners.
The company serves as a collaborative platform to advance next-generation manufacturing technologies for novel modalities. As part of Artis BioSolutions (search), Landmark Bio (search) continues its mission to bring next-generation therapies to patients while maintaining its specialized focus on cell and gene therapy development and manufacturing services.